Wave Life Sciences, Inc. (WVE)
Every FINRA and SEC series the site collects for Wave Life Sciences, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
16.2M
Short interest
settlement 2026-08-14
4.4
Days to cover
-1.2% vs prior
48.8%
Short share of volume
2026-09-11
62,587
Fails to deliver
settlement 2026-08-14
-$135K
Insider flow, 90 days
0 buys, 4 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in WVE is 16,200,874 shares, down 647,886 shares over the last month. Over the last 48 readings it ranged from 3,376,366 shares (30 August 2024) to 20,901,285 shares (30 June 2026). At the reported average volume of 3.7M shares a day that is 4.4 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/wve" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 16,200,874 | -1.2% | 3,689,771 | 4.39 |
| 2026-07-31 | 16,401,737 | -2.6% | 2,200,935 | 7.45 |
| 2026-07-15 | 16,848,760 | -19.4% | 2,674,732 | 6.30 |
| 2026-06-30 | 20,901,285 | +15.1% | 3,678,558 | 5.68 |
| 2026-06-15 | 18,153,025 | -2.0% | 3,250,978 | 5.58 |
| 2026-05-29 | 18,530,652 | +4.3% | 4,053,792 | 4.57 |
| 2026-05-15 | 17,770,733 | +6.3% | 4,281,323 | 4.15 |
| 2026-04-30 | 16,720,976 | +25.3% | 4,035,622 | 4.14 |
| 2026-04-15 | 13,345,828 | +1.0% | 3,390,450 | 3.94 |
| 2026-03-31 | 13,210,972 | -1.5% | 8,794,789 | 1.50 |
| 2026-03-13 | 13,412,705 | -1.8% | 2,138,813 | 6.27 |
| 2026-02-27 | 13,654,126 | -10.5% | 2,517,152 | 5.42 |
| 2026-02-13 | 15,249,091 | +0.5% | 2,496,007 | 6.11 |
| 2026-01-30 | 15,179,480 | -0.1% | 3,854,259 | 3.94 |
| 2026-01-15 | 15,191,594 | +3.4% | 5,392,044 | 2.82 |
| 2025-12-31 | 14,692,409 | +0.0% | 3,107,980 | 4.73 |
| 2025-12-15 | 14,691,352 | -8.3% | 21,559,954 | 1.00 |
| 2025-11-28 | 16,026,900 | +4.0% | 2,063,645 | 7.77 |
| 2025-11-14 | 15,407,887 | +15.3% | 2,795,090 | 5.51 |
| 2025-10-31 | 13,366,828 | +1.7% | 4,098,599 | 3.26 |
| 2025-10-15 | 13,141,809 | -17.1% | 2,142,198 | 6.13 |
| 2025-09-30 | 15,848,243 | -12.2% | 1,889,345 | 8.39 |
| 2025-09-15 | 18,043,501 | +4.2% | 3,005,912 | 6.00 |
| 2025-08-29 | 17,318,028 | +3.4% | 1,547,991 | 11.19 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of WVE volume is 48.8%, up 14.9 points over the last five sessions. Over the last 52 readings it ranged from 21.0% (17 July 2026) to 64.4% (30 June 2026). The latest reading is 10.0 points above the 30-session average of 38.8%, on 797K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 389K | 797K | 48.8% | 122 |
| 2026-09-10 | 467K | 928K | 50.4% | 507 |
| 2026-09-09 | 651K | 1.2M | 54.1% | 2,794 |
| 2026-09-08 | 828K | 1.6M | 53.1% | 0 |
| 2026-09-04 | 338K | 1.2M | 28.4% | 4,665 |
| 2026-09-03 | 808K | 2.4M | 33.9% | 3,394 |
| 2026-09-02 | 711K | 2.4M | 29.8% | 800 |
| 2026-09-01 | 457K | 1.2M | 37.8% | 4,211 |
| 2026-08-31 | 755K | 1.8M | 42.5% | 3,600 |
| 2026-08-28 | 386K | 907K | 42.6% | 0 |
| 2026-08-27 | 644K | 1.3M | 49.5% | 4,000 |
| 2026-08-26 | 374K | 828K | 45.2% | 0 |
| 2026-08-25 | 218K | 907K | 24.1% | 0 |
| 2026-08-24 | 705K | 2.1M | 34.4% | 0 |
| 2026-08-21 | 303K | 1.1M | 26.7% | 0 |
| 2026-08-20 | 380K | 1.1M | 33.6% | 0 |
| 2026-08-19 | 352K | 1.2M | 29.9% | 800 |
| 2026-08-18 | 370K | 1.2M | 30.0% | 0 |
| 2026-08-17 | 430K | 1.3M | 32.0% | 0 |
| 2026-08-14 | 426K | 1.2M | 35.5% | 0 |
| 2026-08-13 | 736K | 2.8M | 25.8% | 10,101 |
| 2026-08-12 | 725K | 2.0M | 36.5% | 38,905 |
| 2026-08-11 | 825K | 3.0M | 27.6% | 79,044 |
| 2026-08-10 | 273K | 709K | 38.6% | 0 |
| 2026-08-07 | 459K | 1.1M | 43.5% | 2,000 |
| 2026-08-06 | 338K | 647K | 52.3% | 306 |
| 2026-08-05 | 227K | 574K | 39.6% | 267 |
| 2026-08-04 | 341K | 770K | 44.3% | 0 |
| 2026-08-03 | 618K | 1.3M | 46.5% | 0 |
| 2026-07-31 | 525K | 1.1M | 46.2% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 14 August 2026, the fails-to-deliver balance in WVE is 62,587 shares, down 37,606 shares over the last settlement date. Over the last 52 readings it ranged from 2 shares (13 April 2026) to 1,537,673 shares (27 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 62,587 | $5.20 | $325K |
| 2026-08-13 | 100,193 | $5.24 | $525K |
| 2026-08-12 | 130,300 | $5.05 | $658K |
| 2026-08-11 | 18,659 | $6.07 | $113K |
| 2026-08-10 | 53 | $6.10 | $323 |
| 2026-07-31 | 62 | $5.76 | $357 |
| 2026-07-29 | 1,000 | $5.89 | $6K |
| 2026-07-16 | 41 | $5.91 | $242 |
| 2026-07-15 | 13,069 | $6.13 | $80K |
| 2026-07-02 | 5 | $5.84 | $29 |
| 2026-06-30 | 89 | $5.68 | $506 |
| 2026-06-26 | 2 | $5.75 | $12 |
| 2026-06-22 | 4,218 | $6.16 | $26K |
| 2026-06-15 | 232 | $5.87 | $1K |
| 2026-06-05 | 1,508 | $6.09 | $9K |
| 2026-06-03 | 40 | $5.69 | $228 |
| 2026-04-24 | 25,000 | $7.31 | $183K |
| 2026-04-23 | 25,000 | $7.38 | $185K |
| 2026-04-20 | 649 | $7.49 | $5K |
| 2026-04-17 | 1,370 | $7.32 | $10K |
| 2026-04-13 | 2 | $7.18 | $14 |
| 2026-04-09 | 17,111 | $7.10 | $121K |
| 2026-04-07 | 3,776 | $7.09 | $27K |
| 2026-04-06 | 38 | $7.28 | $277 |
| 2026-04-01 | 10,760 | $7.25 | $78K |
| 2026-03-31 | 17,178 | $6.62 | $114K |
| 2026-03-27 | 1,537,673 | $6.20 | $9.5M |
| 2026-03-06 | 104 | $13.20 | $1K |
| 2026-02-04 | 3,245 | $13.70 | $44K |
| 2026-02-03 | 187 | $13.43 | $3K |
Insider trades
SEC Form 4, newest first, 50 of 95 shown. JSONInsiders at WVE reported 4 open-market sells worth $135K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Rawcliffe Adrian on 2026-08-12.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-12 | Rawcliffe Adrian | n/a | Sell | 13K | $5.29 | $67K | 0 |
| 2026-08-11 | Wagner Heidi L | n/a | Sell | 7K | $6.01 | $42K | 45K |
| 2026-08-11 | Wagner Heidi L | n/a | Option exercise | 7K | $5.97 | $42K | 52K |
| 2026-08-11 | Tan Aik Na | n/a | Sell | 432 | $6.01 | $3K | 25K |
| 2026-08-11 | TAKANASHI KEN | n/a | Sell | 4K | $6.01 | $23K | 20K |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 971K | $6.50 | $6.3M | 27.0M |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 2.5M | $6.43 | $16.0M | 26.0M |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 351K | $6.38 | $2.2M | 23.5M |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 5.0M | $6.06 | $30.0M | 23.2M |
| 2026-03-23 | TAKANASHI KEN | n/a | Conversion | 3.9M | $0.00 | $0 | 9.6M |
| 2026-02-26 | Francis Chris | See Remarks | Sell | 15K | $15.00 | $229K | 62K |
| 2026-02-26 | Francis Chris | See Remarks | Option exercise | 15K | $4.75 | $73K | 77K |
| 2026-02-26 | Francis Chris | See Remarks | Sell | 18K | $15.09 | $270K | 62K |
| 2026-02-26 | Francis Chris | See Remarks | Option exercise | 18K | $3.87 | $69K | 80K |
| 2026-02-09 | Vargeese Chandra | See Remarks | Sell | 3K | $13.45 | $43K | 408K |
| 2026-02-09 | Moran Kyle | Chief Financial Officer | Sell | 4K | $13.45 | $48K | 134K |
| 2026-02-09 | Francis Chris | See Remarks | Sell | 2K | $13.45 | $25K | 62K |
| 2026-02-09 | BOLNO PAUL | President and CEO | Sell | 10K | $13.45 | $141K | 276K |
| 2026-02-05 | Vargeese Chandra | See Remarks | Grant | 46K | $0.00 | $0 | 411K |
| 2026-02-05 | Moran Kyle | Chief Financial Officer | Grant | 46K | $0.00 | $0 | 138K |
| 2026-02-05 | Francis Chris | See Remarks | Grant | 39K | $0.00 | $0 | 64K |
| 2026-02-05 | BOLNO PAUL | President and CEO | Grant | 165K | $0.00 | $0 | 286K |
| 2026-01-02 | Francis Chris | See Remarks | Sell | 1K | $16.70 | $22K | 25K |
| 2026-01-02 | Francis Chris | See Remarks | Sell | 8K | $15.92 | $129K | 26K |
| 2026-01-02 | Francis Chris | See Remarks | Option exercise | 9K | $3.14 | $29K | 34K |
| 2025-12-11 | GSK plc | n/a | Buy | 1.5M | $19.00 | $27.9M | 18.2M |
| 2025-12-09 | Moran Kyle | Chief Financial Officer | Sell | 50K | $20.02 | $1.0M | 90K |
| 2025-12-09 | Moran Kyle | Chief Financial Officer | Option exercise | 50K | $10.48 | $524K | 139K |
| 2025-12-09 | Moran Kyle | Chief Financial Officer | Sell | 36 | $20.25 | $729 | 89K |
| 2025-12-09 | Moran Kyle | Chief Financial Officer | Option exercise | 36K | $8.17 | $294K | 125K |
| 2025-12-08 | Wagner Heidi L | n/a | Sell | 7K | $13.00 | $91K | 45K |
| 2025-12-08 | Wagner Heidi L | n/a | Option exercise | 7K | $5.97 | $42K | 52K |
| 2025-12-08 | Verdine Gregory L. | n/a | Sell | 8K | $14.05 | $112K | 275K |
| 2025-12-08 | Verdine Gregory L. | n/a | Sell | 12K | $13.09 | $157K | 283K |
| 2025-12-08 | Tan Aik Na | n/a | Sell | 21K | $12.75 | $268K | 25K |
| 2025-12-08 | Tan Aik Na | n/a | Option exercise | 21K | $3.50 | $74K | 46K |
| 2025-12-08 | Tan Aik Na | n/a | Sell | 25K | $15.00 | $375K | 25K |
| 2025-12-08 | Tan Aik Na | n/a | Sell | 20K | $12.75 | $255K | 50K |
| 2025-12-08 | Tan Aik Na | n/a | Option exercise | 45K | $4.58 | $206K | 70K |
| 2025-12-08 | Tan Aik Na | n/a | Sell | 17K | $15.00 | $258K | 25K |
| 2025-12-08 | Tan Aik Na | n/a | Sell | 15K | $12.75 | $191K | 43K |
| 2025-12-08 | Tan Aik Na | n/a | Option exercise | 32K | $5.37 | $173K | 58K |
| 2025-12-08 | Tan Aik Na | n/a | Sell | 7K | $12.75 | $96K | 33K |
| 2025-12-08 | Rawcliffe Adrian | n/a | Sell | 42K | $15.00 | $630K | 13K |
| 2025-12-08 | Rawcliffe Adrian | n/a | Option exercise | 42K | $5.97 | $251K | 55K |
| 2025-12-08 | Moran Kyle | Chief Financial Officer | Option exercise | 50K | $4.75 | $238K | 139K |
| 2025-12-08 | Moran Kyle | Chief Financial Officer | Sell | 50K | $15.00 | $750K | 139K |
| 2025-12-08 | Moran Kyle | Chief Financial Officer | Option exercise | 100K | $3.14 | $314K | 189K |
| 2025-12-08 | Moran Kyle | Chief Financial Officer | Sell | 60K | $13.20 | $792K | 89K |
| 2025-12-08 | Moran Kyle | Chief Financial Officer | Option exercise | 60K | $2.83 | $170K | 149K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for WVE worth $107K at the prices reported; 2 in the last 90 days worth $107K. Latest: ADRIAN G RAWCLIFFE filed on 2026-08-12 to sell 12,700 shares ($64K) from 2026-08-12.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-12 | ADRIAN G RAWCLIFFEDirector | 13K | $64K | 0.006% | 2026-08-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-11 | HEIDI L WAGNERDirector | 7K | $42K | 0.004% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON4 holders above 5% have filed on WVE, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 16.8% of the class (34,314,406 shares), filed 2026-08-11 for an event on 2026-08-07.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-11 | 13D/Ano. 11 | RA Capital Management, L.P.investment adviser, partnership | 34.3M | 16.8% | 2026-08-07 |
| 2026-08-11 | 13D/Ano. 11 | Peter Kolchinskyparent holding company, individual | 34.3M | 16.8% | 2026-08-07 |
| 2026-08-11 | 13D/Ano. 11 | Rajeev Shahparent holding company, individual | 34.3M | 16.8% | 2026-08-07 |
| 2026-08-11 | 13D/Ano. 11 | RA Capital Healthcare Fund, L.P.partnership | 34.1M | 16.7% | 2026-08-07 |
13F holders
Tracked managers holding WVE at their latest 13F. JSON8 of the 30 tracked managers held WVE at their latest 13F, $75.1M in total at quarter-end prices. Two Sigma Investments is the largest at $21.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 3.7M | $21.5M | 0.02% | +1.8M |
| Millennium Management | 2026-06-30 | 1.8M | $10.5M | 0.00% | +1.3M |
| D. E. Shaw & Co. | 2026-06-30 | 1.8M | $10.3M | 0.00% | +1.7M |
| Renaissance Technologies | 2026-06-30 | 1.7M | $9.9M | 0.01% | +1.1M |
| AQR Capital Management | 2026-06-30 | 1.6M | $9.6M | 0.00% | +1.2M |
| Point72 Asset Management | 2026-06-30 | 1.5M | $8.6M | 0.01% | +1.5M |
| Citadel Advisors | 2026-06-30 | 619K | $3.6M | 0.00% | -2.2M |
| Duquesne Family Office | 2026-06-30 | 173K | $1.0M | 0.02% | 0 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) Wave Life Sciences, Inc. reported revenue of $2.3M, down 73.9% from the same quarter a year earlier, and net loss of $69.4M (-0.34 diluted EPS). In FY 2025 it generated -$187.5M of operating cash flow.
- Cash
- $368.0M
- Equity
- $453.5M
- Total assets
- $558.3M
- Shares outstanding
- 197,048,175
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.3M | -$69.4M | -3052.6% | -0.34 |
| Q1 2026 | 2026-03-31 | $38.2M | -$26.1M | -68.2% | -0.13 |
| Q4 2025derived | 2025-12-31 | n/a | -$53.2M | n/a | n/a |
| Q3 2025 | 2025-09-30 | n/a | -$53.9M | n/a | -0.32 |
| Q2 2025 | 2025-06-30 | $8.7M | -$50.5M | -580.2% | -0.31 |
| Q1 2025 | 2025-03-31 | $9.2M | -$46.9M | -510.9% | -0.29 |
| Q4 2024derived | 2024-12-31 | n/a | $29.3M | n/a | n/a |
| Q3 2024 | 2024-09-30 | n/a | -$61.8M | n/a | -0.47 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $42.7M | -$204.4M | -$187.5M | $718K | n/a | n/a |
| FY 2024 | 2024-12-31 | $108.3M | -$97.0M | -$151.0M | $938K | n/a | n/a |
| FY 2023 | 2023-12-31 | $113.3M | -$57.5M | -$19.4M | $1.1M | n/a | n/a |
| FY 2022 | 2022-12-31 | $3.6M | -$161.8M | -$127.8M | $1.4M | n/a | n/a |
| FY 2021 | 2021-12-31 | $41.0M | -$122.2M | -$89.0M | $560K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-23 from the cover page.
What this page is
Wave Life Sciences, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Wave Life Sciences, Inc. (WVE), SEC CIK 1631574, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-08-12.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-11.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-12.JSON and CSV
- Company record
- EDGAR filing index for CIK 1631574Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- LGNDLIGAND PHARMACEUTICALS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LQDALiquidia Corp
- SIONSionna Therapeutics, Inc.
- JAZZJazz Pharmaceuticals plc
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- HOWLWerewolf Therapeutics, Inc.
Datasets
Frequently Asked Questions
How much of WVE is sold short?
What is WVE's daily short volume?
Does WVE have fails to deliver?
Are WVE insiders buying or selling?
Have WVE insiders filed to sell?
Who owns more than 5% of WVE?
What did WVE report last quarter?
Which funds hold WVE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.